Skip to content
Bending the Curve Trial by Trial
?

Back to Hodgkin lymphoma

References: Hodgkin lymphoma

105 sources cited on this page. Links open the primary source.

  1. Hodgkin. On some Morbid Appearances of the Absorbent Glands and Spleen. Med Chir Trans. 1832;17:68-114. PubMedDOISource
    CiteLoading…
  2. Wilks S. Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease) with remarks. Guy's Hosp Rep. 1865;11:56-67. Source
    CiteLoading…
  3. Sternberg C. Ueber eine eigenartige unter dem Bilde der Pseudoleukaemie verlaufende Tuberculose des lymphatischen Apparates. Z Heilkd. 1898;19:21-90. Source
    CiteLoading…
  4. Reed DM. On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133-196. Source
    CiteLoading…
  5. Gilbert R. Radiotherapy in Hodgkin's disease (malignant granulomatosis). Anatomic and clinical foundations; governing principles; results. Am J Roentgenol Radium Ther. 1939;41:198-241.
    CiteLoading…
  6. Peters MV. A study of survivals in Hodgkin's disease treated radiologically. Am J Roentgenol Radium Ther. 1950;63:299-311.
    CiteLoading…
  7. PETERS MV, MIDDLEMISS KC. A study of Hodgkin's disease treated by irradiation. Am J Roentgenol Radium Ther Nucl Med. 1958;79(1):114-21. PubMed
    CiteLoading…
  8. KAPLAN HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 1962;78:553-61. PubMedDOI
    CiteLoading…
  9. Easson EC, Russell MH. Cure of Hodgkin's Disease. Br Med J. 1963;1(5347):1704-7. PubMedDOI
    CiteLoading…
  10. Kaplan HS, Rosenberg SA. Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials. Cancer Res. 1966;26(6):1268-76. PubMed
    CiteLoading…
  11. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73(6):881-95. PubMedDOI
    CiteLoading…
  12. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1. PubMed
    CiteLoading…
  13. Rosenberg SA, Boiron M, DeVita VT Jr, Johnson RE, Lee BJ, Ultmann JE, et al. Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res. 1971;31(11):1862-3. PubMed
    CiteLoading…
  14. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-9. PubMedDOI
    CiteLoading…
  15. DeVita VT Jr, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH 3rd, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92(5):587-95. PubMedDOI
    CiteLoading…
  16. Kaplan HS. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer. 1980;45(10):2439-74. PubMedDOI
    CiteLoading…
  17. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys. 1985;11(1):5-22. PubMedDOI
    CiteLoading…
  18. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4(9):1295-306. PubMedDOI
    CiteLoading…
  19. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-6. PubMedDOI
    CiteLoading…
  20. Rosenfeld L. Hodgkin's disease: origin of an eponym--and one that got away. Bull N Y Acad Med. 1989;65(5):618-32. PubMed
    CiteLoading…
  21. Canellos GP. Is there an effective salvage therapy for advanced Hodgkin's disease?. Ann Oncol. 1991;2 Suppl 1:1-7. PubMedDOI
    CiteLoading…
  22. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-84. PubMedDOI
    CiteLoading…
  23. Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, et al. Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer. 1992;70(10):2508-16. PubMedDOI
    CiteLoading…
  24. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-4. PubMedDOI
    CiteLoading…
  25. Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91(23):10962-6. PubMedDOI
    CiteLoading…
  26. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994;12(2):312-25. PubMedDOI
    CiteLoading…
  27. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12(5):1063-73. PubMedDOI
    CiteLoading…
  28. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4):1495-505. PubMedDOI
    CiteLoading…
  29. Dawson PJ. The original illustrations of Hodgkin's disease. Ann Diagn Pathol. 1999;3(6):386-93. PubMedDOI
    CiteLoading…
  30. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-71. PubMedDOI
    CiteLoading…
  31. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-9. PubMedDOI
    CiteLoading…
  32. Dawson PJ. Whatever happened to Dorothy Reed?. Ann Diagn Pathol. 2003;7(3):195-203. PubMedDOI
    CiteLoading…
  33. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(24):2386-95. PubMedDOI
    CiteLoading…
  34. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21(4):607-14. PubMedDOI
    CiteLoading…
  35. Hoppe RT. The John Ultmann Lecture--the role of radiation therapy in the treatment of Hodgkin's disease: past, present, and future. Eur J Haematol Suppl. 2005;(66):14-20. PubMedDOI
    CiteLoading…
  36. Stone MJ. Thomas Hodgkin: medical immortal and uncompromising idealist. Proc (Bayl Univ Med Cent). 2005;18(4):368-75. PubMedDOI
    CiteLoading…
  37. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-52. PubMedDOI
    CiteLoading…
  38. Cowan DH. Vera Peters and the curability of Hodgkin disease. Curr Oncol. 2008;15(5):206-10. PubMedDOI
    CiteLoading…
  39. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-54. PubMedDOI
    CiteLoading…
  40. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-60. PubMedDOI
    CiteLoading…
  41. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-52. PubMedDOI
    CiteLoading…
  42. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21. PubMedDOI
    CiteLoading…
  43. U.S. Food and Drug Administration. Accelerated approval letter, BLA 125388/0 and 125399/0, ADCETRIS (brentuximab vedotin). 19 August 2011. Source
  44. European Medicines Agency, CHMP. Summary of opinion (initial authorisation), Adcetris, EMA/CHMP/471107/2012. 19 July 2012. Source
  45. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9. PubMedDOI
    CiteLoading…
  46. Geller SA, Taylor CR. Thomas Hodgkin: the "man" and "his disease": humani nihil a se alienum putabit (nothing human was foreign to him). Virchows Arch. 2013;463(3):353-65. PubMedDOI
    CiteLoading…
  47. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-58. PubMedDOI
    CiteLoading…
  48. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-68. PubMedDOI
    CiteLoading…
  49. Raemaekers JM, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188-94. PubMedDOI
    CiteLoading…
  50. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-9. PubMedDOI
    CiteLoading…
  51. U.S. Food and Drug Administration. Supplement approval letter, BLA 125388/S-080 and S-081, ADCETRIS (brentuximab vedotin). e-signed 17 August 2015. Source
  52. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-62. PubMedDOI
    CiteLoading…
  53. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598-607. PubMedDOI
    CiteLoading…
  54. Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med. 2015;373(26):2499-511. PubMedDOI
    CiteLoading…
  55. van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-17. PubMedDOI
    CiteLoading…
  56. Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood. 2016;127(12):1531-8. PubMedDOI
    CiteLoading…
  57. U.S. Food and Drug Administration. Accelerated approval letter, BLA 125554/S-019, OPDIVO (nivolumab). e-signed 17 May 2016. Source
  58. Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016;374(25):2419-29. PubMedDOI
    CiteLoading…
  59. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol. 2016;34(3):235-43. PubMedDOI
    CiteLoading…
  60. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283-94. PubMedDOI
    CiteLoading…
  61. André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35(16):1786-1794. PubMedDOI
    CiteLoading…
  62. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390(10114):2790-2802. PubMedDOI
    CiteLoading…
  63. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125-2132. PubMedDOI
    CiteLoading…
  64. U.S. Food and Drug Administration. Accelerated approval letter, BLA 125514/S-015, Keytruda (pembrolizumab). e-signed 14 March 2017. Source
  65. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428-1439. PubMedDOI
    CiteLoading…
  66. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018;378(4):331-344. PubMedDOI
    CiteLoading…
  67. Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19-iv29. PubMedDOI
    CiteLoading…
  68. U.S. Food and Drug Administration. Supplement approval letter, BLA 125388/S-097, ADCETRIS (brentuximab vedotin). e-signed 20 March 2018. Source
  69. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835-2845. PubMedDOI
    CiteLoading…
  70. U.S. Food and Drug Administration. Supplement approval letter, BLA 125514/S-085, Keytruda (pembrolizumab). e-signed 14 October 2020. Source
  71. Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223-234. PubMedDOI
    CiteLoading…
  72. Flerlage JE, Hiniker SM, Armenian S, Benya EC, Bobbey AJ, Chang V, et al. Pediatric Hodgkin Lymphoma, Version 3.2021. J Natl Compr Canc Netw. 2021;19(6):733-754. PubMedDOI
    CiteLoading…
  73. Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, et al. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022;387(4):310-320. PubMedDOI
    CiteLoading…
  74. Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, et al. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022;387(18):1649-1660. PubMedDOI
    CiteLoading…
  75. U.S. Food and Drug Administration. Supplement approval letter, BLA 125388/S-106, Adcetris (brentuximab vedotin). e-signed 10 November 2022. Source
  76. Munir F, Hardit V, Sheikh IN, AlQahtani S, He J, Cuglievan B, et al. Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int J Mol Sci. 2023;24(12). PubMedDOI
    CiteLoading…
  77. Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024;404(10450):341-352. PubMedDOI
    CiteLoading…
  78. Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, et al. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. J Clin Oncol. 2024;42(1):19-25. PubMedDOI
    CiteLoading…
  79. Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, et al. Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia. 2024;38(1):160-167. PubMedDOI
    CiteLoading…
  80. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024;391(15):1379-1389. PubMedDOI
    CiteLoading…
  81. Moskowitz AJ. Combination chemotherapy for Hodgkin lymphoma. Haematologica. 2024;109(8):2383-4. DOI
    CiteLoading…
  82. European Medicines Agency, CHMP. Assessment report, Adcetris, EMEA/H/C/002455/II/0111, EMA/324858/2025. 25 April 2025. Source
  83. European Medicines Agency, CHMP. Summary of opinion (post authorisation), Adcetris, EMA/CHMP/125287/2025. 25 April 2025. Source
  84. European Medicines Agency. Adcetris: EPAR - Procedural steps taken and scientific information after the authorisation (archive); procedure II/0111 (CHMP opinion 25 April 2025; Commission decision issued 2 June 2025). Source
  85. U.S. Food and Drug Administration. ADCETRIS prescribing information, Indications and Usage, via the openFDA drug label API (label version effective 11 November 2025). Source
  86. Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, et al. Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial. Lancet Oncol. 2025;26(8):1081-1090. PubMedDOI
    CiteLoading…
  87. Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, et al. Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. J Clin Oncol. 2025;43(27):2968-2973. PubMedDOI
    CiteLoading…
  88. Advani RH, Kelsey CR, Armand P, Bello CM, Benitez CM, Bond D, et al. Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(2):41-60. PubMedDOI
    CiteLoading…
  89. Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, et al. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. J Clin Oncol. 2026;44(6):449-454. PubMedDOI
    CiteLoading…
  90. Cancer Research UK. Hodgkin lymphoma survival statistics. Health professional page. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/hodgkin-lymphoma/survival. Page accessed 20 October 2026. Source
  91. ClinicalTrials.gov. NCT02684708 (EuroNet-PHL-C2). Registry record, accessed 20 October 2026. NCT02684708
  92. ClinicalTrials.gov. NCT04685616 (RADAR). Registry record, accessed 20 October 2026. NCT04685616
  93. ClinicalTrials.gov. NCT05675410 (AHOD2131). Registry record, accessed 20 October 2026. NCT05675410
  94. ClinicalTrials.gov. NCT06465446 (IMM01 plus tislelizumab). Registry record, accessed 20 October 2026. NCT06465446
  95. ClinicalTrials.gov. NCT07256158 (FIL PRIORITY). Registry record, accessed 20 October 2026. NCT07256158
  96. European Commission. Union Register of medicinal products for human use: Adcetris (EU/1/12/794), procedure and decision history. Page accessed 20 October 2026. Source
  97. European Commission. Union Register of medicinal products for human use: Opdivo (EU/1/15/1014), procedure and decision history. Page accessed 20 October 2026. Source
  98. Eichenauer DA, André M, Borchmann P, Collins GP, Doherty I, Eich HT, et al. Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Hemasphere. 2026;10(6):e70422. PubMedDOI
    CiteLoading…
  99. European Medicines Agency. Adcetris (brentuximab vedotin): European public assessment report page, EMEA/H/C/002455. Page last updated 20 March 2026. Source
  100. European Medicines Agency, CHMP. Summary of opinion (post authorisation), Opdivo, EMADOC-1700519818-3055572. 23 April 2026. Source
  101. European Medicines Agency. Opdivo (nivolumab): European public assessment report page. Fetched 20 October 2026. Source
  102. European Medicines Agency. Opdivo: EPAR - Procedural steps taken and scientific information after the authorisation; procedure EMA/VR/0000304938 (CHMP opinion 23 April 2026; Commission decision issued 28 May 2026). Source
  103. U.S. Food and Drug Administration. FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma. Content current as of 20 March 2026. Source
  104. U.S. Food and Drug Administration. Supplement approval letter, BLA 125554/S-135, Opdivo (nivolumab). e-signed 20 March 2026. Source
  105. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Hodgkin Lymphoma. Page accessed 20 October 2026; the page displays no update date (HTML metadata and HTTP Last-Modified header: 22 April 2026). Source